Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | TLR7 | Q9NYK1 | 7/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.40 |
| ▸ | CNR2 | P34972 | 1/20 | 0.40 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.39 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.39 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 3/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | HRH2 | P25021 | 1/20 | 0.38 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.38 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.38 |
| ▸ | HTR2B | P41595 | 1/20 | 0.38 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3441040 | 0.90 | TLR7 (0.39) | ALDH1A1TLR7NPSR1HSD17B10KDM4E | |
| SCHEMBL5396347 | 0.87 | TLR7 (0.40) | ALDH1A1TLR7ADORA2AADORA2BADORA1 | |
| SCHEMBL3441092 | 0.85 | TLR7 (0.43) | ALDH1A1TLR7NPSR1HSD17B10KDM4E | |
| SCHEMBL3441043 | 0.82 | HSP90AA1 (0.50) | ALDH1A1TLR7TLR8ADORA2AADORA2B | |
| SCHEMBL3441007 | 0.82 | FBP1 (0.50) | ALDH1A1TLR7NPSR1HSD17B10KDM4E | |
| SCHEMBL3441218 | 0.81 | HSP90AA1 (0.49) | ALDH1A1TLR7TLR8ADORA2AADORA2B | |
| SCHEMBL30515170 | 0.81 | CYP3A4 (0.43) | TLR7 | |
| SCHEMBL3441083 | 0.80 | RXFP1 (0.45) | ALDH1A1TLR7NPSR1HSD17B10KDM4E | |
| SCHEMBL3441078 | 0.80 | MEN1 (0.46) | ALDH1A1TLR7NPSR1HSD17B10KDM4E | |
| SCHEMBL3441254 | 0.80 | TLR7 (0.41) | ALDH1A1TLR7NPSR1HSD17B10KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2200615-A1 | A3 ADENOSINE RECEPTOR ANTAGONISTS | Gilead Palo Alto, Inc. (US) | 2010-06-30 | — | — | EP | disclosed |
| WO-2009052310-A1 | A3 ADENOSINE RECEPTOR ANTAGONISTS | CV THERAPEUTICS, INC (US) | 2009-04-23 | — | — | WO | disclosed |
| US-20090099212-A1 | A3 ADENOSINE RECEPTOR ANTAGONISTS | ZABLOCKI JEFF | 2009-04-16 | — | — | US | disclosed |
| EP-1646390-B1 | A1 ADENOSINE RECEPTOR ANTAGONISTS | CV THERAPEUTICS INC (US) | 2008-10-08 | — | — | EP | disclosed |
| US-7238700-B2 | A2B adenosine receptor antagonists | CV THERAPEUTICS, INC. (US) | 2007-07-03 | — | — | US | disclosed |
| EP-1646390-A1 | A1 ADENOSINE RECEPTOR ANTAGONISTS | CV THERAPEUTICS, INC. (US) | 2006-04-19 | — | — | EP | disclosed |
| US-7022710-B2 | A1 adenosine receptor antagonists | CV THERAPEUTICS, INC. (US) | 2006-04-04 | — | — | US | disclosed |
| EP-1401837-B1 | PURINE DERIVATIVES AS A2B ADENOSINE RECEPTOR ANTAGONISTS | CV THERAPEUTICS INC (US) | 2005-10-19 | — | — | EP | disclosed |
| US-20050059683-A1 | A1 adenosine receptor antagonists | CV THERAPEUTICS, INC. | 2005-03-17 | — | — | US | disclosed |
| WO-2005009445-A1 | A1 ADENOSINE RECEPTOR ANTAGONISTS | CV THERAPEUTICS, INC. (US) | 2005-02-03 | — | — | WO | disclosed |
| US-20040209899-A1 | A2B adenosine receptor antagonists | PALLE VENKATA (IN) | 2004-10-21 | — | — | US | disclosed |
| US-6770651-B2 | THERAPY FOR ASTHMA, DIARRHEA | PALLE VENKATA (US) | 2004-08-03 | — | — | US | disclosed |
| EP-1401837-A1 | PURINE DERIVATIVES AS A2B ADENOSINE RECEPTOR ANTAGONISTS | CV THERAPEUTICS, INC. (US) | 2004-03-31 | — | — | EP | disclosed |
| US-20030064999-A1 | A2B adenosine receptor antagonists | PALLE VENKATA (US) | 2003-04-03 | — | — | US | disclosed |
| WO-2003006465-A1 | PARTIAL AND FULL AGONIST OF A ADENOSINE RECEPTORS | CV THERAPEUTICS, INC. (US) | 2003-01-23 | — | — | WO | disclosed |
| WO-2003002566-A1 | PURINE DERIVATIVES AS A2B ADENOSINE RECEPTOR ANTAGONISTS | CV THERAPEUTICS, INC. (US) | 2003-01-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030064999-A1 | A2B adenosine receptor antagonists | ADORA2B, ADORA2A, ADORA1 | ALDH1A1 734/4885TLR7 1635/4885NPSR1 1018/4885 |
| US-20090099212-A1 | A3 ADENOSINE RECEPTOR ANTAGONISTS | ADORA3, ADORA2A, ADORA2B | ALDH1A1 831/4885TLR7 2170/4885NPSR1 129/4885 |
| US-20040209899-A1 | A2B adenosine receptor antagonists | ADORA2B, ADORA2A, ADORA1 | ALDH1A1 520/4885TLR7 854/4885NPSR1 433/4885 |
| US-20050059683-A1 | A1 adenosine receptor antagonists | ADORA1, ADORA2A, ADORA3 | ALDH1A1 468/4885TLR7 2128/4885NPSR1 76/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.